4.7 Article

miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway

Journal

CLINICAL CANCER RESEARCH
Volume 23, Issue 4, Pages 1091-1103

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-16-0943

Keywords

-

Categories

Funding

  1. Department of Defense Breast Cancer Research Program [W81XWH-09-1-0331, W81XWH-16-1-0021]
  2. Paul Calabresi K12 Award [1K12CA139160-02]
  3. University of Chicago Cancer Center Support Grant [CA 014599]
  4. Case Western Reserve University start-up fund
  5. NIH/NCI [K99/R00 CA160638-02]
  6. Case Comprehensive Cancer Center Pilot Project [P30 CA043703-23]
  7. American Cancer Society [ACS127951-RSG-15-025-01-CSM]
  8. Susan G. Komen Breast Cancer Foundation [CCR15332826]
  9. Ohio Cancer Research Associates Seeding Grant
  10. Northern Ohio Golf Charities Foundation
  11. Case Comprehensive Cancer Center VelaSano Bike for Cure Pilot grant

Ask authors/readers for more resources

Purpose: Effective targeting of cancer stem cells is necessary and important for eradicating cancer and reducing metastasis-related mortality. Understanding of cancer stemness-related signaling pathways at the molecular level will help control cancer and stop metastasis in the clinic. Experimental Design: By analyzing miRNA profiles and functions in cancer development, we aimed to identify regulators of breast tumor stemness and metastasis in human xenograft models in vivo and examined their effects on self-renewal and invasion of breast cancer cells in vitro. To discover the direct targets and essential signaling pathways responsible for miRNA functions in breast cancer progression, we performed microarray analysis and target gene prediction in combination with functional studies on candidate genes (overexpression rescues and pheno-copying knockdowns). Results: In this study, we report that hsa-miR-206 suppresses breast tumor stemness and metastasis by inhibiting both self-renewal and invasion. We identified that among the candidate targets, twinfilin (TWF1) rescues the miR-206 phenotype in invasion by enhancing the actin cytoskeleton dynamics and the activity of the mesenchymal lineage transcription factors, megakaryoblastic leukemia (translocation) 1 (MKL1), and serum response factor (SRF). MKL1 and SRF were further demonstrated to promote the expression of IL11, which is essential for miR-206's function in inhibiting both invasion and stemness of breast cancer. Conclusions: The identification of the miR-206/TWF1/MKL1-SRF/IL11 signaling pathway sheds lights on the understanding of breast cancer initiation and progression, unveils new therapeutic targets, and facilitates innovative drug development to control cancer and block metastasis. (C)2016 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available